Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing...

Published on 18 Feb 2024 on Zacks · via Yahoo Finance

The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we...

Insider Monkey · via Yahoo Finance 2 Oct 2024

Immunovant, Inc. IMVT reported fourth-quarter fiscal 2024 net loss of 52 cents per share, wider t...

Zacks via Yahoo Finance 30 May 2024

Immunovant, Inc. IMVT is a New York-based biopharmaceutical company, which develops monoclonal an...

Zacks via Yahoo Finance 22 Apr 2024

Investors might want to bet on Immunovant, Inc. (IMVT), as it has been recently upgraded to a Zac...

Zacks via Yahoo Finance 17 Apr 2024

It has been about a month since the last earnings report for Immunovant, Inc. (IMVT). Shares have...

Zacks via Yahoo Finance 13 Mar 2024

On February 22, 2024, Eva Barnett, the Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT), s...

GuruFocus.com via Yahoo Finance 24 Feb 2024

The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically ...

Zacks · via Yahoo Finance 18 Feb 2024

Immunovant, Inc. IMVT reported fiscal third-quarter 2024 net loss of 36 cents per share, narrower...

Zacks via Yahoo Finance 13 Feb 2024

<img src=https://s.yimg.com/ny/api/res/1.2/JLTYz_3_gnjesFzGTkeyTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O...

GuruFocus.com via Yahoo Finance 13 Feb 2024